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Background: As formula diets have demonstrated to be effective in reducing weight, we 46 
hypothesized that in patients with overweight or obesity and accompanied cardiovascular risk 47 
factors, combining a liquid formula diet with a lifestyle intervention is superior in reducing 48 
weight and improving cardiovascular risk factors than lifestyle intervention alone.  49 
Methods: In this multicenter RCT 463 participants with overweight or obesity (BMI: 27-35 50 
kg/m²; at least one additional co-morbidity of the metabolic syndrome) were randomized (1:2) 51 
into either a control group with lifestyle intervention only (CON, n=155) or a lifestyle 52 
intervention group including a liquid meal replacement (INT, n=308). Both groups used 53 
telemonitoring devices (scales and pedometers), received information on healthy diet and were 54 
instructed to increase physical activity. Telemonitoring devices automatically transferred data 55 
into a personalised online portal and acquired data were discussed. INT obtained a liquid meal 56 
replacement substituting three meals/day (~1,200 kcal) within the first week. During weeks 2-4, 57 
participants replaced two meals/day and during weeks 5-26 only one meal/day was substituted 58 
(1,300-1,500 kcal/day). Follow-up was conducted after 52 weeks. Intention-to-treat analyses 59 
were performed. Primary outcome was weight change. Secondary outcomes comprised changes 60 
in cardiometabolic risk factors including body composition and laboratory parameters. 61 
Results: From the starting cohort 360 (78%, INT: n=244; CON: n=116) and 317 (68%, INT: 62 
n=216; CON: n=101) participants completed the 26-weeks intervention phase and the 52-weeks 63 
follow-up. The estimated treatment difference (ETD) between both groups was -3.2 kg [-4.0; -64 
2.5] (P<0.001) after 12 weeks and -1.8 kg [-2.8; -0.8] (P<0.001) after 52 weeks.  65 
4 
Conclusions: A low-intensity lifestyle intervention combined with a liquid meal replacement is 66 
superior regarding weight reduction and improvement of cardiovascular risk factors than lifestyle 67 




A high energy intake combined with low physical activity are major determinants for 71 
overweight and obesity and contribute to the overall increase of non-communicable diseases [1].  72 
Although lifestyle interventions have been shown to induce clinically relevant effects, 73 
adherence to these approaches remains low overall. Therefore, alternative treatment strategies 74 
need to be considered [2, 3]. In this context, liquid meal replacements have been shown to be an 75 
useful treatment option to manage obesity and diseases such as type 2 diabetes [4-6], leading to 76 
improvements in fat mass, blood pressure, HbA1c, or insulin [7, 8]. Furthermore, there is a 77 
positive association between partial and complete meal replacement with weight reduction which 78 
was shown in favor of complete meal replacement in patients with type 2 diabetes [9]. Based on 79 
their positive effects in the management of patients with type 2 diabetes, liquid meal 80 
replacements have been included into current guidelines for baseline treatment of type 2 diabetes 81 
[10-12], but not uniformly for the routine management of overweight and obesity [3]. In this 82 
regard, there is still uncertainty about weight maintenance and long-term effectivity of formula 83 
diets [13, 14] and whether there is a beneficial effect of adding a formula diet to an lifestyle 84 
intervention and/or nutrition counseling alone in patients with overweight and obesity [12].  85 
Hence, an international and multicenter RCT, the Almased Concept against Overweight 86 
and Obesity and Related Health Risk (ACOORH)-study, was conducted to examine the impact 87 
of a liquid meal replacement together with a low-intensity lifestyle intervention compared to a 88 
low-intensity lifestyle intervention alone on weight loss in patients with overweight or obesity 89 




Materials/Subjects and Methods 93 
 94 
Study design and population 95 
Participating volunteers (n=463) were randomly allocated with a ratio of 1:2 into either a 96 
lifestyle intervention group (CON, n=155) or a meal replacement-based lifestyle intervention 97 
group (INT, n=308). The lifestyle intervention was characterized by a 26-week intervention 98 
phase and a follow-up phase until week 52 and the study design has been described in detail 99 
previously in a predefined subanalysis of the ACOORH study focusing solely on patients with 100 
prediabetes [15]. This multicenter RCT received ethical approval (registered at drks.de; ID: 101 
DRKS00006811) for each participating center and the study reporting adheres to CONSORT 102 
guidelines. Informed consent was obtained from all participating volunteers. Study participants 103 
were recruited in all study centers either through direct contacting based on existing patient files, 104 
(2) proactive study enquiry by the participants via the study center homepages, or (3) 105 
advertisements in newspapers. Inclusion and exclusion criteria have been described in detail 106 
previously [15]. 107 
 108 
Intervention and diet regime 109 
Both groups were provided with guideline booklets about healthy cooking, received 110 
advices regarding physical activity and a healthy lifestyle including encouragement to lose 111 
weight, and were equipped with telemetric scales (smartLAB scale W; HMM Holding AG, 112 
Dossenheim, Germany) and pedometers (smartLAB walk P+; HMM Holding AG, Dossenheim, 113 
Germany). Probands were recommended to note down a 4-day, unweighted diet record at 114 
baseline and after 12, and 52 weeks of the study and all records (including steps and body 115 
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weight) were discussed during the study visits (personal contact time ≈ 1-2 h per visit). A 116 
detailed description of the study can be found elsewhere [15] and is illustrated in Fig. 1. 117 
Additionally, the INT group was provided with the liquid soy-yogurt-honey-based meal 118 
replacement Almased-Vitalkost® (protein content: 53.3% (83 % soy-protein-isolate, and 17% 119 
milk protein), glycemic index (GI): 27, energy per 100 g powder: 1507 kJ (360 kcal), Almased-120 
Wellness-GmbH, Bienenbüttel, Germany [16]) for the first 26 weeks and received an 121 
accompanying booklet containing information about preparing and applying the liquid formula 122 
diet and general advices about low-carbohydrate, low-glycemic and protein-rich meals. The 123 
management of the liquid formula diet regime during the study is described in detail elsewhere 124 
[15]. All booklet records were evaluated at each visit by study nurses and used for nutritional and 125 
lifestyle counselling. 126 
 127 
Measurements 128 
Measurements were performed at baseline as well as after 4, 12, 26, and after 52 weeks 129 
as described in detail elsewhere [15]. Body composition (Seca medical Body Composition 130 
Analyzer® (seca-mBCA 115), Hamburg, Germany [17]) and blood pressure (Mobil-O-Graph 131 
PWA; I.E.M. GmbH, Stolberg, Germany) were determined by using validated devices. 132 
Biochemical blood parameters were determined by venous blood sampling. Adverse and serious 133 
adverse events [18] were documented continuously (participant questionnaire) and were 134 




Sample size calculation was based on the results of a previous study [19] and its 138 
assumptions, including randomization and number of dropouts, are described in detail elsewhere 139 
[15]. Final sample size per group comprised at least 19 participants for each study center.  140 
However, based on previous experiences in all participating centers with dropout rates greater 141 
than 50% for long-term adherence to weight management programs, at least a number of 40 142 
participants per center was targeted. 143 
Primary outcome of the ACOORH study was body weight in kg after 4, 12, 26 and 52 144 
weeks of intervention. Power calculation was performed for the difference of body weight 145 
change after 12 weeks of intervention between INT and CON. Secondary outcomes comprised 146 
changes in anthropometric (fat mass (FM), fat free mass (FFM), and waist circumference (WC)) 147 
and clinical parameters (fasting blood glucose (FBG), systolic blood pressure (SBP), diastolic 148 
blood pressure (DBP), total cholesterol, HDL cholesterol (HDL-C), LDL cholesterol (LDL-C), 149 
TG) after 4, 12, 26 and 52 weeks of intervention. 150 
An independent institute (ACOMED statistik®, Leipzig, Germany) executed the 151 
statistical analysis and a detailed description including statistical tests applied (for parametric and 152 
non-parametric data) and software used can be found elsewhere [15]. Completer (per-protocol 153 
(PP)) and intention-to-treat (ITT) analyses were applied. All statistical tests were two-sided and 154 
significance was assumed at α<0.05. Participants who visited all follow-up assessments were 155 
integrated into the PP analysis. Primary analysis focused on the ITT approach as these values are 156 
of more clinical relevance. Last-observation-carried-forward (LOCF) method was applied to 157 





Four hundred thirty-nine (95%, INT: n=299; CON: n=140) from the starting cohort 162 
finished the first 4 weeks of the intervention phase. Follow-up data after 12, 26 and 52 weeks 163 
were available from 396 (86%, INT: n=270; CON: n=126), 360 (78%, INT: n=244; CON: 164 
n=116) and 317 participants (68%, INT: n=216; CON: n=101). Anthropometric and clinical 165 
parameters of INT and CON at baseline are illustrated in Table 1. Dropouts demonstrated no 166 
statistical difference in comparison to the non-dropout group (Supplementary Table 1). 167 
Participants dropped out because of (1) health issues, (2) work-related issues, (3) personal issues 168 
and (4) other reasons. No acute cardiac event, hospitalization for cardiovascular disease, or other 169 
serious adverse events related to the study participation occurred. 170 
Compared to CON, INT significantly lost more weight after 4 weeks (-4.0 kg with 95% 171 
CI [-4.3;-3.8] vs. -1.4 kg [-1.8;-1.1]; P<0.001), 12 weeks (-5.8 kg with 95% CI [-6.3;-5.3] vs. -172 
2.7 kg [-3.3;-2.1]; P<0.001), 26 weeks (-5.9 kg with 95% CI [-6.5;-5.4] vs. -3.0 kg [-3.8;-2.2]; 173 
P<0.001) and 52 weeks (-4.4 kg [-5.0;-3.8] vs. -2.7 kg [-3.0;-2.0]; P<0.001) in the ITT analysis. 174 
The estimated treatment difference (ETD) between both groups was -2.6 kg [-3.5; -1.8] 175 
(P<0.001) after 4 weeks, -3.2 kg [-4.0; -2.5] (P<0.001) after 12 weeks, -2.9 kg [-3.7; -2.1] 176 
(P<0.001) after 26 weeks and -1.8 kg [-2.8; -0.8] (P<0.001) after 52 weeks. These differences 177 
were even stronger in the PP analysis after 4 weeks (-4.5 kg with 95% CI [-4.8;-4.2] vs. -1.6 kg 178 
[-2.0;-1.2] P<0.001), 12 weeks (-6.3 kg with 95% CI [-6.8;-5.8] vs. -3.2 kg [-3.9;-2.6] P<0.001), 179 
26 weeks (-6.8 kg with 95% CI [-7.5;-6.2] vs. -3.6 kg [-4.6;-2.7] P<0.001) and 52 weeks (-5.0 kg 180 
[-5.7;-4.2] vs. -3.5 kg [-4.5;-2.5] P=0.021).  181 
Weight reduction was accompanied with changes in WC, FM, FBG, SBP, DBP, total 182 
cholesterol, TG, and LDL-C in both groups following the intervention, with a particularly 183 
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pronounced effect within the first 12 weeks (Fig. 2) (ITT analysis). These effects were already 184 
evident after 4 weeks of intervention in all parameters in the INT group (all P<0.001) (ITT 185 
analysis), but not in the CON group. Only FM, WC, and SBP (all P<0.001) as well as DBP and 186 
total cholesterol (both P<0.01) significantly changed after 4 weeks in CON (ITT analysis). The 187 
aforementioned 12-week changes remained significantly altered after 26 weeks of intervention in 188 
the INT group in all parameters (P<0.001) (ITT analysis). In contrast, only FM, WC, and SBP 189 
remained significantly changed after 26 weeks in the CON group (all P<0.01) (ITT analysis). 190 
Compared to CON, INT significantly reduced more WC, FM, FFM, total cholesterol, and 191 
LDL-C after 12 weeks of intervention (Table 2). These differences remained significant after 52 192 
weeks in FM, FFM, and. INT reduced FM by -3.3 kg with 95% CI [-3.9; -2.7] vs. -2.4 kg [-3.2; -193 
1.5] P=0.020) and) compared to CON after 52 weeks. INT showed a pronounced loss in FFM 194 
compared to CON after 52 weeks (-0.9 kg [-1.3; -0.6] vs. -0.3 kg [-0.9; 0.2] P<0.001). 195 
 196 
Discussion 197 
The results of the ACOORH trial show that a low-intensity lifestyle intervention 198 
accompanied with a liquid formula diet contributes to larger reductions in body weight in 199 
patients with overweight or obesity and accompanied cardiovascular risk factors compared to a 200 
low-intensity lifestyle intervention alone and these findings remain significantly superior even 201 
after 52 weeks.  202 
The weight reduction after 1 year (-5.8 kg [-6.3; -5.3] (ITT analysis)) is comparable to 203 
other lifestyle intervention programs with smaller cohorts (n=19-167), which have also shown a 204 
significant weight loss ranging from -1.43 kg to -12.1 kg [20]. In particular, very intense lifestyle 205 
programs with rigorous meal replacement regimen [21] or intensive support [22] led to mean 206 
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weight losses greater than 10 kg. Furthermore, study effects and weight loss show a dose-207 
response pattern in relation to program duration [23] and intensity of support [20]. The longer the 208 
intensive intervention phase and the greater the level of support, the greater the weight loss.  209 
A recently published systematic review and meta-analysis demonstrated larger weight 210 
reductions following either very low (<800 kcal/day) or low-calorie (>800 kcal/day) liquid meal 211 
replacements (ranging from 8.9 to 15.0 kg) in patients with obesity (BMI: 36-43 kg/m²) [24]. 212 
Compared to the present study can be assumed that the weight reduction difference to the studies 213 
in the meta-analysis is resulted by a higher calorie intake per day (1300-1500 kcal/day). In 214 
addition, we chose a more moderate daily energy intake target to increase study compliance and 215 
adherence as well as to minimise dropout rates. In support of this approach, it has been shown 216 
that a moderate and continuous weight loss reduces the risk for adverse outcomes in the long-217 
term compared to a fast and severe weight loss [25]. 218 
In the present study, weight reduction was accompanied with further improvements, 219 
(predominantly achieved in the INT-group) during the 12-week intervention phase in 220 
cardiometabolic parameters, including FM, WC, DBP and LDL-C and TC. Furthermore, after 52 221 
weeks of follow-up there was still a significant difference in FM loss between both groups. 222 
These findings are in line with other lifestyle intervention trials with low-calorie diets in patients 223 
with prediabetes [7] or type 2 diabetes [26, 27] or lifestyle interventions with physical activity in 224 
patients with obesity [28]. 225 
The ACCORH trial and its strengths are characterized by (1) a comparably large sample 226 
size in an (2) international and multicenter design with (3) a randomized controlled trial 227 
approach. Moreover, (4) two intervention groups were followed up over a period of 52 weeks 228 
and this trial was conducted in a (5) real-world setting in which a low-intensity lifestyle 229 
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intervention was combined with liquid meal replacement. The intention was to design a practical 230 
lifestyle-based intervention program which could be easily implemented into present health care 231 
programs. Moreover, the (6) inclusion of only high-risk participants with at least one additional 232 
co-morbidity of the metabolic syndrome indicates a further strength of the study.  233 
There are also limitations in the present trial that have to be considered. We did not 234 
constantly (i) controlled the participants for decreased energy intake or for false food 235 
compositions (e.g., amount of carbohydrates or proteins) by monitoring diet diaries. As it is well-236 
known that dietary records of patients with obesity are characterized by systematic errors, we, 237 
therefore, had purposely chosen not to constantly monitor these records [29]. However, the 238 
prepared 4-day diet diaries of the probands were used in each study visit as a resource of 239 
information for the lifestyle counseling. Moreover, volunteers of the INT group should record 240 
the number of containers and amount of meal replacement consumed. Thus, we were able, at 241 
least, to evaluate the intake of liquid meal replacement within the first 12 weeks. A second 242 
limitation was the imputation of missing values by the LOCF approach. More sophisticated 243 
imputation methods like multiple imputation could have been performed as this imputation 244 
technique takes the uncertainty of the imputed values more realistic into account. However, the 245 
LOCF procedure was consciously chosen as it is a conservative statistical approach to estimate 246 
treatment effects, which might have even underestimated the results. Concomitantly, the ITT 247 
analysis method performed prevents the overestimation of data and takes the number of dropouts 248 
into account. 249 
In sum, a low-intensity lifestyle intervention accompanied with a liquid meal replacement 250 
contributes to a long-term and clinically relevant weight reduction in patients with overweight 251 
and obesity and further cardiovascular risk factors. Furthermore, this weight reduction was 252 
13 
characterized with improvements in cardiovascular and cardiometabolic risk factors. The present 253 
findings underline the efficacy of the liquid formula diet tested in individuals with overweight or 254 
obesity and accompanied cardiovascular risk factors when included in a lifestyle intervention 255 
program. This therapy approach should be considered as a valid option for management of 256 
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Figure legends 380 
Fig.1. Flow diagram. 381 
 382 
Fig. 2. Mean changes in secondary outcomes.  383 
(A) weight, (B) systolic blood pressure (C) diastolic blood pressure, (D) LDL-C, (E) total 384 
cholesterol, (F) fasting blood glucose, (G) waist circumference, (H) triglycerides, and (I) fat 385 
mass after 4, 12, 26, and 52 weeks. Within-group changes were analyzed using ANOVA with 386 
repeated measures. ***p<0.001 vs. baseline; **p<0.01 vs. baseline; *p<0.05 vs. baseline; ITT, 387 
intention-to-treat analysis 388 
 389 
Table legends 390 
Table 1. Baseline characteristics.  391 
Data are presented as means ± standard deviations, or percentages. BMI, body mass index; DBP, 392 
diastolic blood pressure; FBG, fasting blood glucose; FM, fat mass; FFM, fat free mass; HC, hip 393 
circumference; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; SBP, systolic blood 394 
pressure; WC, waist circumference; WHR, waist-to-hip ratio 395 
 396 
Table 2. Intra and intergroup changes in the INT and CON-group after 12 and 52 weeks 397 
compared to baseline 398 
Data are shown as mean [95% CI]. ***p<0.001 vs. baseline; **p<0.01 vs. baseline; *p<0.05 vs. 399 
baseline. Differences in changes after 12 as well as 52 weeks between both groups were analyzed 400 
using ANCOVAs adjusting for baseline values. DBP, diastolic blood pressure; FBG, fasting 401 
19 
blood glucose; FM, fat mass; FFM, fat free mass; HDL-C, HDL cholesterol; LDL-C, LDL 402 
cholesterol; n.a., not available; SBP, systolic blood pressure; WC, waist circumference 403 
404 
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Table 1. Baseline characteristics 1 
 INT-group (n=308) CON-group (n=155) 
Sex (% male) 32.8 41.3 
Age (years) 51 ± 10 50 ± 10 
Weight (kg) 92 ± 14 94 ± 12 
BMI (kg/m²) 31.7 ± 2.4 31.5 ± 2.4 
WC (cm) 106 ± 10 107 ± 8 
HC (cm) 113 ± 8 112 ± 7 
WHR 0.94 ± 0.08 0.95 ± 0.08 
FM (kg) 37.0 ± 6.7 37.0 ± 6.6 
FFM (kg) 54.9 ± 11.7 56.7 ± 11.5 
FBG (mg/dl) 94 ± 12 94 ± 11 
SBP (mmHg) 134 ± 15 134 ± 13 
DBP (mmHg) 89 ± 12 89 ± 10 
Total cholesterol (mg/dl) 221 ± 39 220 ± 45 
HDL-C (mg/dl) 56 ± 15 56 ± 15 
LDL-C (mg/dl) 141 ± 34 139 ± 39 
Triglycerides (mg/dl)   145 ± 83 147 ± 68 
Data are presented as means ± standard deviations, or percentages. BMI, body mass index; 2 
DBP, diastolic blood pressure; FBG, fasting blood glucose; FM, fat mass; FFM, fat free mass; 3 
HC, hip circumference; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; SBP, systolic 4 
blood pressure; WC, waist circumference; WHR, waist-to-hip ratio 5 
Table 2. Intra and intergroup changes in the INT and CON-group after 12 and 52 weeks compared to baseline 1 
ITT (INT, n=307; CON, n=154) 
PP (INT, n=266; CON, n=126) 12w 
PP (INT, n=214; CON, n=101) 52w 
12 weeks 52 weeks 
INT CON P (INT vs. CON) INT CON 















































































































-4.0 [-5.4; -2.7]*** -2.4 [-4.3; -0.4]* 0.069 -2.0 [-3.8; -0.2]* -0.9 [-3.5; 1.7] 0.221 
Total cholesterol  




-16 [-19; -13]*** 
 
-2 [-6; 2] <0.001 
 
-6 [-9; -2]** 
 
-0 [-5; 4] 
 
0.076 





-1 [-2; 0] 
 
0 [-1; 2] 0.002 
 
2 [1; 3]** 
 
2 [0; 3]* 
 
0.858 





-12 [-15; -10]*** 
 
-1 [-4; 2] <0.001 
 
-7 [-10; -4]*** 
 
-2 [-6; 1] 
 
0.067 
-12 [-15; -9]*** -0 [-4; 3] <0.001 -4 [-7; -1]* -4 [-8; 1] 0.736 
Triglycerides  
(mg/dl)                  ITT 
PP 
 
-19 [-27; -11]*** 
 
-10 [-25; 5]*** 0.161 
 
-11 [-20; -3]*** 
 
-9 [-20; 3]* 
 
0.618 
-22 [-30; -14]*** -11 [-29; 8]*** 0.132 -12 [-21; -4]** -15 [-30; -1]* 0.840 
Data are shown as mean [95% CI]. ***p<0.001 vs. baseline; **p<0.01 vs. baseline; *p<0.05 vs. baseline. Differences in changes after 12 as well as 2 
52 weeks between both groups were analyzed using ANCOVAs adjusting for baseline values. DBP, diastolic blood pressure; FBG, fasting blood 3 
glucose; FM, fat mass; FFM, fat free mass; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; n.a., not available; SBP, systolic blood pressure; 4 
WC, waist circumference 5 
